Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
about
Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosisSurvivin: a unique target for tumor therapySurvivin: A molecular biomarker in cancerSurvivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignanciesSurvivin as a target for new anticancer interventionsTargeting survivin in cancer therapySurvivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancerAssessment of mRNA splice variants by qRT-PCR.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma.Association of survivin splice variants with prognosis and treatment of breast cancer.Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR.Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivinMicroRNA regulation and therapeutic targeting of survivin in cancer.Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancerClinicopathological and prognostic significance of survivin expression in patients with oral squamous cell carcinoma: evidence from a meta-analysisEvaluation of survivin splice variants in pituitary tumors.Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis.The proto-oncogene survivin splice variant 2B is induced by PDGF and leads to cell proliferation in rheumatoid arthritis fibroblast-like synoviocytes.The role of survivin in diagnosis, prognosis and treatment of breast cancer.Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.Survivin study: an update of "what is the next wave"?Suppressed diversity of survivin splicing in active rheumatoid arthritis.Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas.Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment.Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivoChk2 phosphorylation of survivin-DeltaEx3 contributes to a DNA damage-sensing checkpoint in cancer.Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges.Survivin: a target from brain cancer to neurodegenerative disease.Survivin in skin pathologies.Survivin in solid tumors: rationale for development of inhibitors.Clinico-pathologic relevance of Survivin splice variant expression in cancerRelationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region.Survivin splice variants and their diagnostic significance.Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide.An integrated PCR microfluidic chip incorporating aseptic electrochemical cell lysis and capillary electrophoresis amperometric DNA detection for rapid and quantitative genetic analysis.Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.Terminally differentiated neutrophils predominantly express Survivin-2 alpha, a dominant-negative isoform of survivin.
P2860
Q24295217-BB555F79-DF19-424F-8D70-7CA184017F18Q26747332-84E40092-CC8A-4796-AE97-E2BB8B32A766Q26823439-62710230-49E9-4315-A709-B0A9C0CD89D1Q28251858-320B4338-A56D-41B1-9CDE-C30122A1A3F8Q28257235-B9CB3946-A1E4-44E0-B254-49077B3212E7Q28273083-67BE6835-A88E-4408-80E2-009A6881A380Q28306223-0DC42F51-E546-469E-8BB5-ABEEFCDA5655Q33765915-6731BA03-708D-4CDD-9573-A06061A4976AQ34195072-26DC354A-424E-4166-9AD8-9AD266A78D54Q34299904-DCEA7450-EA86-4977-B0B7-4D543E8360BDQ34657717-94DDCF13-FA34-4A49-BC6E-FAF0AFD0C398Q34757482-D2D6FC6C-9D31-46C1-94CB-47E7FDB1F2F2Q34871780-F3E1159C-8D61-4DC0-8521-3785BF89EE42Q34991312-EE3DACC5-FEF3-4A16-A845-5C0E5A12690FQ35024933-2757B287-4B34-4DB2-A3AE-0923F8F1F542Q35119245-774D60FF-4631-4FA2-BBD3-0AC933B9566AQ35582889-AD8E1248-08F2-4FE8-B70D-1419773A3B16Q35628857-8110BFCB-9BFC-4792-B61A-372E778E5B39Q35635793-DD32AC9D-DD90-4299-B4F3-C95E478ABB6BQ35667653-6D5CAFCA-CA6D-4111-9A04-6DCC1CB2A385Q35668616-BDDF3CC8-E20C-4F02-9D4D-1F7CE9941420Q36430244-DD0148FF-500A-4AB3-9B6B-CD19AC68E5EAQ36433351-D29AED53-2D98-4607-93B9-369819868D77Q36473904-3BEEEDA6-7360-454B-AC91-8337271DFC98Q36682871-BF805E96-BE75-4AD2-AA6B-41D7E2C4B5EDQ36930279-A7D96290-A69C-40B1-9D96-9AC35BB13193Q36963631-E31B7C04-E247-451C-B3F8-1A754016AFC7Q37064709-03A25B0B-5D2B-45B1-8361-6200733B4526Q37424024-55F7C880-741F-47CD-9F6F-EE1A5E6FF617Q37798272-0EC1C983-D3D9-4572-9A82-92F68A56C4F5Q37876468-6433EA50-E2A0-4190-BB79-C0AEA8FC3080Q37974867-31B06735-D6F7-460E-86EE-9353E2451D5FQ38116267-8179B06B-5351-463E-9C6C-D7D3C368191EQ38416237-D872CF64-1FF6-4CF5-8A1D-9E9AC6EA11EAQ38561421-484845C9-9F67-4C21-98D8-255D3F609CD5Q38738898-C9D725EE-85EF-4B6B-BD98-FE28E6D4606AQ39275796-8484DE1E-30C8-412E-8B13-47CCCA019495Q39282920-6BC212FE-028E-42CC-9559-DB7176A7BBC9Q39697634-E7AD529C-F2DE-40D2-96D4-CF62D28F1798Q40061181-C8EC9EFE-A70F-474D-9EAE-ECC17C67AE24
P2860
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@ast
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@en
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@nl
type
label
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@ast
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@en
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@nl
prefLabel
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@ast
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@en
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@nl
P2093
P2860
P3181
P356
P1433
P1476
Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies
@en
P2093
Hugo Caldas
Laura E Honsey
Rachel A Altura
P2860
P2888
P3181
P356
10.1186/1476-4598-4-11
P407
P577
2005-01-01T00:00:00Z
P5875
P6179
1028902283